{"schema_version":"secwatch.filing_event.v1","accession":"0001808805-24-000055","form_type":"8-K","ticker":"NAUT","cik":"0001808805","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2024-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.599661+00:00","generated_at":"2026-05-31T15:23:07.665949+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Nautilus Biotechnology reports Q2 2024 net loss of $18M, operating expenses up 9% YoY","bullets":["Net loss of $18.0M in Q2 2024 vs $15.8M in Q2 2023.","Operating expenses of $20.8M, up $1.8M or 9% from $19.0M a year ago.","Cash, equivalents, and investments of $232.9M as of June 30, 2024.","Expense increase driven by higher headcount to support product development.","Company continues development of single-molecule proteome analysis platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001808805-24-000055","json":"https://secwatch.observer/filing/0001808805-24-000055.json","markdown":"https://secwatch.observer/filing/0001808805-24-000055.md","text":"https://secwatch.observer/filing/0001808805-24-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000055/0001808805-24-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000055/naut-20240730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:23:07.665949+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}